ClinicalTrials.gg

Program

LY4336619

A development code.

Its studies are mostly in Endometrial Neoplasms, led by Eli Lilly.

Furthest: phase 1, since Nov 5, 20261 company-led study, 1 open or runningNext primary completion: Mar 2032 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Nov 5, 2026Nov 5, 2026Mar 2032phase 1 · NCT07928258

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07928258 · 370 planned · United States, France, Japan and more

Ahead

  1. Mar 2032Primary completion: phase 1 study in Endometrial NeoplasmsNCT07928258

TargetBeta

ALPG →read by rule
“A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors”study text, by rule · the study

Other programs on ALPG

ProgramCompanyFurthest phaseStudies
EMB-15ruleshanghai-epimab-biotherapeutics-co-ltdphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07928258Endometrial Neoplasms · United States, France, Japan and more1Not yet recruitingMar 2032370

How it is read

Names in the registry

  • “LY4336619”, 1 entry

Codes read as this program: LY4336619.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.